IP Library Granted Patent US 9,611,311
Granted Patent B2
US 9,611,311 · App. 14/611,460 · Granted Apr 4, 2017

Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same

Inventors: Paul Boulange (Orsay, FR); Sami Chtourou (Elancourt, FR); Stephane Boyer (Pecqueuse, FR); Roland Schmitthaeusler (Montigny le Bretonneux, FR); Bruno Padrazzi (Paris, FR)
Assignee: LABRATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
C07K14/76C07K1/34C07K14/755C07K14/765A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,611,311
App. No.
14/611,460
Granted
Apr 4, 2017
Kind
B2
Abstract

The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not lass than 7, to nanofiltration in a temperature range of between 15 DEG C and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

Claims (13)

1. A method for purifying an albumin solution containing virus particles to produce a virally safe albumin solution comprising a step of submitting an aqueous albumin solution, with a concentration of 15 g/L to 80 g/L, an ionic strength in the range of 0.01 to 0.3M, and a pH not lower than 7, to a nanofiltration carried out on qualified filters having porosities of 15±2 nm to 20 nm±2 nm in a temperature range of 15° C. to 55° C.

2. The method according to claim 1 wherein the pH of the aqueous albumin solution is in the range of 7.8 to 11.5.

3. The method according to claim 1 , wherein the ionic strength is provided by the addition of a pharmaceutically acceptable salt of an alkali metal.

4. The method according to claim 3 , wherein the salt of an alkali metal is sodium chloride present in an amount imparting to the albumin solution an ionic strength of 0.15 M.

5. The method according to claim 1 , wherein the concentration of the aqueous albumin solution is in the range of 40 g/L to 60 g/L.

6. The method according to claim 1 , wherein the temperature of the aqueous albumin solution is between 30° C. and 55° C.

7. The method according to claim 1 , wherein the nanofiltration of the aqueous albumin solution is carried out in two successive steps on two filters with decreasing porosities, respectively.

8. The method according to claim 7 , wherein the two successive nanofiltration steps are carried out on filters with porosities of 23 to 50 nm and 15 or 20 nm, respectively.

9. The method according to claim 1 , wherein it is implemented with regenerated cellulose filters of 15 nm having a surface area of 0.01 m 2 , at a pressure not exceeding 1 bar.

10. The method according to claim 9 , wherein the pressure is in the range of 0.2 to 0.8 bar.

11. The method according to claim 1 , wherein the albumin is obtained by ethanol extraction and by purification by ion-exchange or affinity chromatography.

12. The method according to claim 1 , further comprising a subsequent step of processing the aqueous albumin solution to make it suitable to a therapeutic use.

13. The method according to claim 1 , wherein the pH of the aqueous albumin solution is in the range of 9 to 10.5.

Assignments (2)
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Apr 3, 2023
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 063237/0439 →
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Sep 21, 2022
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 061493/0885 →
Priority Claims (1)
FR 04 02001 · Feb 27, 2004 · national
Continuity (2)
Continuation 10589825
Related Publication 20150152162A1 · Jun 4, 2015